Condition: Residual, Progressive or Recurrent Grade II or III Meningioma · Sponsor: Neonc Technologies, Inc.
This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable patients. NEO100 will be self-administered four times daily on a 28-day treatment cycle until disease progression, death or patient withdraw from study for any reason, whichever occurs first.
This description comes directly from the study's public registry record.
Chris Beardmore · 224 218 2408 · chris@anovaevidence.com
Chloe Richmond · 224 218 2408 · chloe@anovaevidence.com
Always discuss trial participation with your own doctor first.
| University of Southern California | Los Angeles, California, United States | Recruiting |
| Sutter Health Research Institute | San Francisco, California, United States | Recruiting |
| Saint John Cancer Institute | Santa Monica, California, United States | Recruiting |
| Tufts Medical Center | Boston, Massachusetts, United States | Recruiting |
| Baylor Scott and White | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05023018